Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,488,962 protect, and when does it expire?

Patent ► Subscribe protects JENTADUETO XR, XARTEMIS XR, PROQUIN XR, GRALISE, GLUMETZA, and SYNJARDY XR, and is included in six NDAs. There have been zero Paragraph IV challenges on Xartemis XR, Gralise, and Glumetza.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: ► Subscribe

Title:	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Abstract:	The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
Inventor(s):	Berner; Bret (El Granada, CA), Louie-Helm; Jenny (Union City, CA)
Assignee:	DepoMed, Inc. (Menlo Park, CA)
Application Number:	09/598,061
Patent Claim Types: see list of patent claims	Dosage form;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	► Subscribe	► Subscribe	Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	► Subscribe	► Subscribe	Y
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		RX	Yes	Yes	► Subscribe	► Subscribe	Y
Depomed Inc	PROQUIN XR	ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021744-001	May 19, 2005		DISCN	No	No	► Subscribe	► Subscribe	Y
Depomed Inc	GRALISE	gabapentin	TABLET;ORAL	022544-001	Jan 28, 2011	BX	RX	Yes	Yes	► Subscribe	► Subscribe	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country	Document Number	Estimated Expiration
Austria	256455	► Subscribe
Australia	2001239893	► Subscribe
Australia	3989301	► Subscribe
Canada	2412671	► Subscribe
Germany	60101581	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview